Building Health, Restoring Independence

Company

Targacept's clinical pipeline is built on a unique class of therapeutic targets.

Targacept Inc.

100 North Main Street, Suite 1510

Winston-Salem, NC 27101

Therapeutic Focus:

Gastrointestinal/genitourinary disease

Therapeutic Targets:

Neuronal nicotinic receptors (NNRs)

Product Candidates:

TC-6499, Diabetic Gastroparesis

Number of Employees:

30

Date Established:

March 1997

IPO Completed:

April 2006

NASDAQ Ticker Symbol:

TRGT

Targacept Company Overview – Expertise in the Field of NNRs
Targacept, TRGT, NNR Therapeutics, neuronal nicotinic receptors, NNR, neuronal nicotinic acetylcholine receptors, nicotinic acetylcholine receptors, nAChR, nicotinic, nicotinic agonist, nicotinic antagonist, nervous system disorders, nicotinic channel modulator, central nervous system disorders, CNS, AAMI, cognition, Parkinson’s disease, l-dopa-induced dyskinesia
Targacept is a leader in NNRs, with more than 20 years of NNR-focused research and development.